Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease

In RCT (n=334), single IV infusion of revacept, 160 mg or 80 mg, prior to the start of PCI on top of standard antithrombotic therapy, did not reduce myocardial injury in patients with stable ischaemic heart disease undergoing percutaneous coronary intervention vs. placebo.

JAMA Cardiology